PharmGen Science, Inc.
KOSPI
₩3,025.00
-0.33%
Delayed · cached 15 min
Fair value analysis
004720
PharmGen Science, Inc.
₩3,025.00
Close used for this calculation
₩4,713.55Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
63/100
Quality radar
Consensus fair value
₩4,713.55
Below FV▲ +55.8% against the close used
Model range ₩1,540.00 – ₩10,575.49
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩1,540.00Fair value₩4,713.55Bull₩10,575.49
FairClose
52-week traded range
52W low ₩2,710.0052W high ₩4,570.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
PharmGen Science, Inc. closed at ₩3,025.00, 35.8% below the consensus fair value of ₩4,713.55 drawn from 9 valuation models.
Financial DNA score 63/100 — Good. P/E of 19.6x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩1,605.84
-46.9%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₩6,902.45
+128.2%
√(22.5 × EPS × BVPS)
EPS=154, BVPS=13750
Graham Formula
₩9,958.67
+229.2%
EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate
g=20%, FD=3.3%
P/E Fair Value
₩3,080.00
+1.8%
EPS × 20x (sector P/E)
EPS=154, Sector P/E=20x
Peter Lynch (PEG)
₩4,620.00
+52.7%
EPS × Growth% (PEG = 1 is fair)
EPS=154, g=30%
EV/EBITDA
₩10,575.49
+249.6%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=10.64B
Book Value (P/B)
₩1,540.00
-49.1%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=13750, ROE=1.1%, g=6%, r=10%
Reverse DCF
₩3,025.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 6.9% | Historical: 63.9%
Margin of Safety
₩4,040.06
+33.6%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=5386.74, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.